Introduction
Semaglutide is a long-acting GLP-1 receptor agonist extensively described in metabolic research and clinical literature. VialVibes supplies research-use-only material for qualified laboratory investigation. Research materials are distinct from FDA-approved pharmaceutical products (e.g., branded medicines) and must not be used as substitutes for approved drugs.
Chemical and structural summary
GLP-1 receptor agonist peptide analog. Lyophilized research material. CAS 910463-68-2 commonly listed. Confirm identity/purity on lot CoA.
| Catalog name | Semaglutide |
|---|---|
| Category | Metabolic Research |
| CAS | 910463-68-2 |
| Molecular weight note | About 4113.6 g/mol (reference) |
| Documentation | Lot-specific CoA available on request |
Research history and background
GLP-1 biology and GLP-1 receptor agonists are central to modern metabolic research. Semaglutide has been studied in large clinical programs for type 2 diabetes and weight management as approved medicines in those regulated contexts. Laboratory research also uses incretin analogs as tool compounds under appropriate institutional controls.
Areas investigated in laboratory and preclinical research
The following themes appear in peer-reviewed literature. Inclusion here means the topic has been studied or reviewed scientifically - not that catalog materials are validated for any endpoint.
- GLP-1 receptor signaling and incretin biology in experimental systems
- Metabolic pathway research informed by the broader clinical literature on GLP-1 receptor agonists
- Comparative pharmacology research among incretin-based peptides
Mechanisms discussed in the literature
As a GLP-1 receptor agonist, semaglutide is described as engaging receptors involved in glucose-dependent insulin secretion, glucagon pathways, gastric emptying, and central appetite-regulation circuits in research and clinical literature. Those descriptions concern the molecule class and approved-drug contexts; they are not directions for using RUO research material in humans.
Key published studies and reviews
Prefer primary literature. Open links in a new tab. Always read full papers for methods and limitations.
- Chao AM, Wadden TA. (2023). Semaglutide for the treatment of obesity. Trends Cardiovasc Med. PubMed 34942372.
- Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond (review). PubMed 40281304.
- Kommu S, et al. Semaglutide - StatPearls. NCBI Bookshelf NBK603723. https://www.ncbi.nlm.nih.gov/books/NBK603723/
Known limitations and evidence gaps
Do not conflate RUO research peptides with FDA-approved semaglutide medicines. Clinical trial results for approved products do not authorize unregulated use of research materials. Institutional review and legal compliance remain buyer responsibilities.
Laboratory handling notes
General laboratory practice for lyophilized peptides includes cool, dry storage protected from moisture and light, careful reconstitution with appropriate research diluents, and documentation of lot numbers. See educational guides for process literacy - not product-specific validated stability claims.
- Storage and stability of lyophilized peptides
- Reconstitution best practices for laboratory use
- Reconstitution calculator (concentration and aliquot volume math)
- How to read a Certificate of Analysis
Regulatory status note
Materials sold by VialVibes are Research Use Only. They are not intended for human consumption, clinical administration, or veterinary use, and are not sold as FDA-approved drugs. Where the scientific literature discusses approved medicines or investigational drug programs involving the same active structure class, those regulated products remain distinct from RUO research reagents. See Research Use Only - what it means and the legal RUO policy.